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Abstract 
Background:  The non-medical use of prescription opioids is a significant problem in the United 
States, with significant health and economic consequences.  The nationwide implementation and 
expansion of prescription drug monitoring programs (PDMPs) has been utilized to reduce the 
incidence of doctor shopping, influence prescribing practices, and improve patient treatment 
decisions.  
Objective: The purpose of this paper is to describe the available primary literature on 
prescription drug monitoring programs. 
Methods: Peer reviewed research articles, literature reviews, and opinion articles on prescription 
drug monitoring programs from 2000 to 2017 were identified by searching PubMed/Medline, 
CINAHL, Embase, PsycInfo, using ‘prescription drug monitoring programs’ OR ‘PDMP’ OR 
‘prescription monitoring programs’ AND ‘opioids’ as search terms or MeSH terms.  Article 
bibliographies were also search manually for applicable papers. 
Results:  Nineteen primary research articles were included for analysis.  Evidence of impact of 
prescription drug monitoring programs on opioid-related outcomes is inconclusive. 
Conclusions:  As PDMP implementation continues to expand, there needs to be continued focus 
on specific PDMP characteristics to determine what is the most effective at reducing opioid-
related outcomes. 
Key Words: prescription monitoring programs, diversion, drug, prescription drug abuse, 
controlled substances 
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Background 
Importance and impact 
Pain is a serious health issue that affects more patients than heart disease, cancer and 
diabetes mellitus combined.1,2  It is the most commonly cited reason that Americans utilize the 
healthcare system; it is also the current leading cause of disability and remains a major 
contributor to healthcare costs.2  As a result, there has been an expansion in pharmacologic 
treatments for pain and the rates of controlled substance prescriptions for pain, specifically 
opioids, have increased.3  Analyses performed by the United States Food and Drug 
Administration (FDA) found that between 1998 and 2010, retail opioid sales have increased by 
242%.4,5  Studies have shown that the increased prescribing rate of opioids is correlated with a 
significant rise in misuse, addiction, and opioid-related overdoses. 
The Centers for Disease Control and Prevention (CDC) describes the upsurge in opioid-
related overdose deaths in three distinct waves.  The first wave began in the early 1990s and is 
characterized by the rise in opioid prescriptions, with a subsequent increase in prescription 
opioid-related overdose deaths.  The second wave is marked by the rise in heroin-related 
overdose deaths that began in 2010.  Lastly, the third wave in 2013 is distinguished by the 
increase in synthetic opioid-related overdose deaths, particularly those involving illicitly-
manufactured fentanyl.6  In 2010, opioid-related overdose deaths substantially surpassed deaths 
from any other drug class.7  By 2016, death rates related to opioids, including prescription 
opioids, heroin, and illicitly-manufactured fentanyl, had increased five-fold since 1999.6 
Doctor shopping 
 The rise in popularity and utilization of opioids is accompanied by an upsurge in drug 
diversion activities.8  In 2008, the United States Department of Justice found that doctor 
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shopping is a principle method for obtaining controlled substances for illegitimate (non-medical) 
use.9,10  The term “doctor shopping” describes patients that receive multiple prescriptions for 
controlled substances from multiple providers.11  According to a 2013 report from the Substance 
Abuse and Mental Health Services Administration (SAMHSA), only 3.1 percent of survey 
respondents indicated doctor shopping as a source of obtaining prescription pain relievers for 
non-medical use.12  The latest available data from the National Survey on Drug Use and Health 
in the United States showed that there were 11.5 million non-medical users of prescription 
opioids in 2016, a greater than ten percent increase from 2002.13,14 
A study conducted by the United States Government Accountability Office (GAO) found 
that over 170,000 Medicare beneficiaries received prescriptions for controlled substances from 
five or more medical providers.  Of those Medicare beneficiaries, 600 received prescriptions 
from 21 to 87 medical providers.  The results of this 2008 study lead to the 2011 testimony of 
GAO managing director, Gregory Kutz, to conclude that the United States government has been 
supporting and disguising an addiction to prescription drugs.10  
The economic burden of prescription drug diversion is estimated to be approximately $72 
billion per year.  Financial costs are associated with increased healthcare costs, productivity loss, 
criminal activity, and incarceration.15,16  In 2016, in response to the rapid increase in drug 
diversion and abuse, the United States Office of National Drug Control Policy (ONDC) called 
for a 15% reduction in prescription drug abuse and diversion with a recommendation to expand 
prescription drug monitoring programs nationwide.17 
Prescription drug monitoring programs  
In the 1990s, prior to the prevalence of electronic databases, the United States had a 
paper-prescription monitoring program, known as ‘triplicate prescriptions’ or ‘multiple copy 
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prescriptions’.  It required medical providers to use triplicate prescription pads for controlled 
substances, with one copy going to the pharmacy, one to the prescribing provider, and one to the 
state.  Providers could access a patient’s controlled substance prescription history after 
submitting a written request in the mail.  Due to this lengthy process, triplicate prescriptions do 
not allow for real-time assessment of a patient’s controlled substance dispensing history.  
Because paper programs were time-consuming, burdensome, and expensive, they were 
ultimately considered ineffective against drug diversion activities.18 
Prescription drug monitoring programs (PDMPs) replaced paper programs and were 
started in the United States in 2003.  They serve to function as easily-accessible statewide 
electronic databases that collect prescribing and dispensing data of controlled substances.  
Pharmacists are required to enter prescriptions of controlled substances, as specified by the 
governing state, into the database.  Registered medical providers can conveniently access patient 
data to check the quantity and types of controlled substances prescribed for patients by other 
providers.18,19  
As of 2017, all 50 states and Washington D.C. have operational PDMPs.  Missouri’s 
PDMP remains the only program that is not operational state-wide.20  This paper seeks to 
describe published peer-reviewed scientific literature focused on prescription drug monitoring 
programs.  Existing literature will be reviewed to discuss: the impact of prescription drug 
monitoring programs on (1) the prescribing practices of opioids, (2) patient behavior, and (3) 
opioid-related population health outcomes.  
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Methods 
Search strategies 
 The primary objective of this paper is to identify, review, and describe the available 
evidence regarding the impact of prescription drug monitoring programs on opioid-related 
outcomes.   Peer-reviewed research articles, literature reviews, and opinion articles on 
prescription drug monitoring programs were identified by initially searching PubMed/Medline.  
CINAHL, Embase, and PsycInfo were used as alternative databases.  The majority of literature 
on prescription drug monitoring programs were primarily published between 2001 and 2012.21  
To ensure inclusion of relevant studies, articles published between 2000 and 2017 were included 
in the search.  The keywords and MeSH terms used were: “prescription drug monitoring 
programs”, “PDMP”, and “opioid”.  The initial search results yielded 166 unique articles.  
Systematic reviews, commentaries, editorials, and non-United States studies were excluded.  
Nineteen relevant articles and studies were identified using this approach.  An additional five 
articles were identified and reviewed from manually searching article references for applicable 
papers.  Most studies were excluded from our analysis because of their editorial nature.  Several 
studies were also excluded because their impact analyses combined prescription opioids with 
other controlled substances, such as benzodiazepines. 
Table 1.  Summary of Search Methods 
Primary objective: Describe available literature regarding impact of prescription drug monitoring 
programs on the following opioid-related outcomes: (1) opioid-prescribing 
behavior, (2) patient behavior, and (3) opioid-related health outcomes. 
Keywords, MeSH terms: “prescription drug monitoring programs” OR “PDMP” OR “prescription 
monitoring programs” AND “opioid” 
 
Additional studies were identified using article references. 
Published dates: 1/1/2000-12/31/2017 
Inclusion criteria: English language, human, original primary research, direct assessment of 
outcomes related to impact of PDMP implementation. 
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Study selection: Abstracts and titles were reviewed, and irrelevant and duplicate articles were 
identified.  Systematic reviews, commentaries, and non-United States studies 
were excluded. 
 
Data synthesis and analysis 
The full text of original articles that met inclusion criteria were reviewed and examined.  
Articles were divided into three distinct categories: the impact of PDMPs on (1) opioid 
prescribing behavior, (2) patient behavior, and (3) opioid-related health outcomes.  Among the 
articles identified, a wide range of research design and primary endpoint variables were 
employed.  To prevent the author from excluding relevant and important study findings, a 
decision was made to use a data chart to summarize research findings.  
Results 
Table 2.  Characteristics of Included Studies. 
Domain 1: Impact of PDMPs on opioid prescribing behavior 
First Author, Year Study Period Setting Data Source 
Bao, 2016 2001-2010 24 states National Ambulatory Medical Care Survey 
Moyo, 2017 2007-2012 10 states Opioid prescription claims among Medicare beneficiaries 
Wen, 2017 2011-2014 46 states Medicaid drug utilization data 
Baehren, 2010 2008 Single-center ED
a 
(Toledo, OH) 
Study-specific pre- and post-PDMPa review 
survey 
Weiner, 2013 2011-2013 2 urban trauma centers (Massachusetts) 
Study-specific pre- and post-PDMP review 
survey 
Paulozzi, 2011b 1999-2005 50 states and Washington D.C. 
Automation of Reports and Consolidated 
Orders System 
Brady, 2014 1999-2008 50 states and Washington D.C. 
Automation of Reports and Consolidated 
Orders System 
Rasubala, 2015 2012-2014 New York Electronic medical records at dental urgent care center 
Rutkow, 2015 2010-2012 Florida, Georgia IMS Health LifeLink LRx database 
Brown, 2017 b 2010-2015 New York Automation of Reports and Consolidated Orders System 
Chang, 2016 2010-2012 Florida, Georgia IMS Health LifeLink LRx database 
Simoni-Wastila, 2012 2007 50 states and Washington D.C. 
Coordination of Benefits Market Scan 
claims data 
Domain 2: Impact of PDMPs on patient behavior 
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First Author, Year Study Period Setting Data Source 
Meara, 2016b 2006-2012 50 states and Washington D.C. Medicare medical claims data 
Surratt, 2014 2010-2011 Florida RADARSa System 
Reifler, 2012b 2003-2009 50 states and Washington D.C. 
RADARS System Poison Center and 
Opioid Treatment surveillance databases  
Ali, 2017 2004-2014 50 states and Washington D.C. National Survey of Drug Use and Health 
Domain 3: Impact of PDMPs on population health outcomes 
First Author, Year Study Period Setting Data Source 
Li, 2014 1999-2008 50 states and Washington D.C. 
National Center for Health Statistics 
database 
Meara, 2016 b 2006-2012 50 states and Washington D.C. Medicare medical claims data 
Patrick, 2016 1999-2013 35 states LawAtlas database, WONDERa database 
Pardo, 2017 1999-2014 50 states and Washington D.C. WONDER database 
Paulozzi, 2011b 1999-2005 50 states and Washington D.C. National Center for Health Statistics 
Reisman, 2009 1997-2003 50 states and Washington D.C. Treatment Episode Data Sets 
Reifler, 2012 b 2003-2009 50 states and Washington D.C. 
RADARS System Poison Center and 
Opioid Treatment surveillance databases  
Delcher, 2015 2003-2012 Florida Florida Medical Examiners Commission 
Maughan, 2015 2004-2011 11 multi-state metropolitan areas Drug Abuse Warning Network 
Brown, 2017 b 2010-2015 New York Statewide Planning and Research Cooperative System 
Young, 2017 1999-2014 50 states and Washington D.C. 
National Center for Health Statistics 
database and WONDER database 
Phillips, 2017 2011-2014 50 states and Washington D.C. WONDER database 
a ED emergency department; PDMP prescription drug monitoring program; RADARS research, abuse, diversion, and 
addiction-related surveillance; WONDER wide-ranging online data for epidemiologic research 
b Article findings address more than one domain of opioid-related outcomes. 
 
Research Findings 
 The following tables provide a summary of the articles reviewed.  A data chart was 
formulated to extract outcome measures, study design, primary study findings, and whether the 
study provides findings indicative of a significant impact on opioid-related outcomes.  The 
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articles were further subdivided based on key domains of impact: (1) opioid prescribing 
behavior, (2) patient behavior, and (3) opioid-related health outcomes. 
Table 3.  Studies of Prescription Drug Monitoring Program Impact on Opioid Prescribing 
Behavior (Domain 1) 
First 
Author, 
Year  
Outcome Measure Design/Methods Findings 
Evidence 
for PDMP 
Impact 
Ba
o,
 2
01
6 
[22
]  
§ Prescription of at 
least one Schedule 
IIa opioid 
analgesic 
§ Prescription of at 
least one opioid of 
any kind.   
Comparison:  24 PDMPb 
states  
Control:  non-PDMP 
states 
Time: 2011-2014 
Statistical method: linear 
probability regression 
model 
PDMP implementation was 
associated with a greater than 
30% reduction in the rate of 
prescribing Schedule II opioids.  
 
Yes 
M
oy
o,
 2
01
7 
[23
] 
§ Monthly total 
opioid volume 
§ Mean daily MMEb 
dose per 
prescription 
§ Number of opioid 
prescriptions 
dispensed 
§ Total opioid 
volume dispensed 
Comparison:  14 PDMP 
states  
Control:  5 geographically 
proximal non-PDMP states 
Time: 2007-2012 
Statistical method: 
interrupted time-series 
regression analyses 
PDMP implementation was 
associated with reduced 
monthly total opioid volume (-
2.36 kg/month) and no changes 
in mean MMEs or opioid 
prescriptions dispensed 
compared to non-PDMP states. 
Yes 
W
en
, 2
01
7 
[24
] 
§ Number of filled 
prescriptions (both 
new prescriptions 
and refills) 
§ Amount of pre-
rebate Medicaid 
spending on 
prescription 
opioids 
Comparison:  PDMP 
states with registration or 
use mandates 
Control:  PDMP states 
with no mandates 
Time: 2007-2012 
Statistical method: linear 
regression model 
PDMP mandates of any kind 
(either registration or use) were 
associated a nine to ten percent 
reduction in population-
adjusted numbers of Schedule 
II opioids. 
Yes 
Ba
eh
re
n,
 2
01
0 
[25
]  
§ Change in opioid 
prescription 
writing from 
predicted before 
PDMP database 
review 
Comparison: ED provider 
assessment post-PDMP 
review 
Control:  ED provider 
assessment pre-PDMP 
review 
Time: Jun – Jul 2008 
Statistical method: 
descriptive statistics 
After reviewing patient in 
PDMP, overall opioid 
prescribing was altered for 
41% of patients.  In cases of 
altered management, 61% 
resulted in fewer or no opioid 
medications prescribed 
compared with pre-PDMP 
assessment.   
Yes 
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W
ei
ne
r, 
20
13
 [2
6 ]  
§ Change in opioid 
prescription 
writing from 
predicted before 
PDMP database 
review 
Comparison: ED provider 
assessment post-PDMP 
review 
Control:  ED provider 
assessment pre-PDMP 
review 
Time:  2011-2013 
Statistical method: 
multiple logistic regression 
analysis 
ED providers changed plans to 
prescribe opioids in 9.5% of 
cases, with 6.5% of patients 
receiving opioids not 
previously planned.   
No 
Pa
ul
oz
zi
, 2
01
1 
[27
]  
§ MME rates of 
opioid 
consumption 
Comparison: 19 PDMP 
states 
Control:  31 non-PDMP 
states 
Time:  1999-2005 
Statistical method: linear 
regression models for 
multiple parallel time 
series (panel regression) 
PDMP and non-PDMP states 
had almost identical mean 
MME rates each year and over 
the entire study period.  
 
MME rates from Schedule III 
opioids were significantly 
higher (about 20 MME/person) 
in PDMP states compared with 
non-PDMP states.b 
No 
Comparison: 13 
proactivec PDMP states 
Control:  6 non-proactive 
PDMP states 
Time:  1999-2005 
Statistical method: linear 
regression models for 
multiple parallel time 
series (panel regression) 
Proactive PDMP states did not 
have lower MME rates than 
other PDMP states. 
 
Analysis for individual states 
showed that three states had 
significantly lower use of 
prescription opioid drugs. 
No 
Br
ad
y,
 2
01
4 
[28
] 
§ MME of opioids 
dispensed per 
person 
Comparison: 31 PDMP 
states 
Control:  19 non- PDMP 
states 
Time:  1999-2008 
Statistical method: linear 
regression model 
There was no statistically 
significant difference in MMEs 
dispensed with and without 
PDMPs. 
 
Effect varied markedly by state 
(significantly fewer in nine 
states, no significant effect in 
14 states, and a significant 
increase in eight states). 
No 
Comparison: PDMP 
states with certain 
characteristicsd 
Control:  PDMP states 
without certain 
characteristics.  
Time:  1999-2008 
Statistical method: linear 
regression model 
The amount of MMEs 
dispensed was less in PDMPs 
with the following features: 
§ Governed by state health 
departments. 
§ No statutory requirements 
for committee oversight. 
§ No laws that explicitly 
impose no expectation on 
providers to access 
statewide electronic 
PDMP data. 
No 
Prescription drug monitoring programs: a response to the opioid epidemic    9 
 
Ra
su
ba
la
, 2
01
5 
[29
]  
§ Frequency of 
opioid 
prescriptions 
§ Quantity of opioid 
prescriptions 
Comparison: post-PDMP 
implementation in a single 
dental urgent care in New 
York (NY) State 
Control:  pre-PDMP 
implementation in a single 
dental urgent care in NY 
State 
Time:  2012-2014 
Statistical method: 
descriptive statistics 
Compared to pre-PDMP, the 
odds for a patient to receive 
opioid analgesics was reduced 
by 58% (ORb 0.42) in the first 
three-months post-PDMP and 
72% (OR 0.28) in the second 
three-months post-PDMP.   
 
By the end of the study, the 
total absolute quantity of 
opioids prescribed was reduced 
by 78%.    
Yes 
Ru
tk
ow
, 2
01
5 
[30
] 
§ Total opioid 
volume supply 
(MME doses) 
§ Mean MME per 
transaction 
§ Days’ supply per 
transaction 
§ Total number of 
opioid 
prescriptions 
dispensed 
Comparison: Florida 
(PDMP and pill mill lawse) 
Control:  Georgia (no 
PDMP and pill mill laws) 
Time:  2010-2012 
Statistical method: 
interrupted time-series 
analysis 
When comparing pre-PDMP 
and post-PDMP periods in 
Florida, total opioid volume in 
FL was significantly reduced 
(2.5 kg/month).  Mean MME 
per transaction was 
significantly reduced (0.45 
mg/month). 
 
There was no apparent effect 
on days’ supply per transaction 
or on total number of opioid 
prescriptions dispensed.   
Yes 
Ch
an
g,
 2
01
6 
[31
]  
Comparison:  high-risk 
prescribersf in Florida 
(PDMP and pill mill lawse) 
Control:  low-risk 
prescribers in Florida, 
Georgia 
Time:  2010-2012 
Statistical method: 
interrupted time-series 
analysis 
When comparing the impact of 
PDMPs on high-risk providers 
versus low-risk providers, 
there was clinically significant 
reductions in monthly trends in 
the following outcomes: 
§ Number of patients with 
an opioid prescription (-
536 patients/month) 
§ Average MME per 
transaction (-0.88 
MME/month/transaction) 
§ Total opioid volume (-
3.88 kg/month) 
§ Number of opioid 
prescriptions (-847 
prescriptions/month) 
Yes 
Br
ow
n,
 2
01
7 
[32
]  
§ Annual MME of 
opioids 
§ Total number of 
opioid 
prescriptions 
dispensed 
Comparison:  post-PDMP 
Control:  pre-PDMP 
Time:  2010-2015 
Statistical method: 
interrupted time-series 
analysis 
There was a significant decline 
in distribution of MMEs prior 
to PDMP implementation with 
a significant increase following 
implementation. 
 
Not enough data was available 
to draw a conclusion about the 
trend in the number of opioid 
prescriptions filled post-PDMP 
implementation.  
No 
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Si
m
on
i-W
as
til
a,
 2
01
2 
[33
 ]  
§ Odds of receiving 
opioid prescription 
Comparison:  28 PDMP 
states 
Control:  22 non-PDMP 
states 
Time:  2007 
Statistical method: 
logistic regression analysis 
Among analgesic users, the 
odds of receiving Schedule II 
opioids was lowest in states 
with combined electronic 
PDMPs and serialized 
prescription overlay (OR 0.54), 
followed by states with only 
electronic PDMPs (OR 0.76) 
relative to non-PDMP states.  
Yes 
a  Controlled substances are divided into five schedules with Schedule I having the highest potential for abuse and 
strictest regulations and Schedule V having the lowest potential for abuse.  In 2014, the Drug Enforcement Agency 
(DEA) reclassified a major subclass of Schedule III opioids (combination drugs containing hydrocodone, such as 
Vicodin and Lortab) to Schedule II. 
b  PDMP prescription drug monitoring program; MME morphine milligram equivalent; ED emergency department; 
OR odds ratio 
c  Proactive PDMPs are defined as those generating reports for prescribers, dispensers, or law enforcement 
authorities without being solicited. 
d  Individual PDMP characteristics that were compared were (1) the PDMP governing agency, (2) the statutory 
requirements for committee oversight, and (3) presence of explicit laws that impose no expectation on providers.  
e  Pill mill laws required clinics to register with the state and have a physician-owner, created inspection 
requirements, and established prescribing and dispensing requirements and prohibitions for physicians at these 
clinics.  
f  High-risk providers were identified as providers in the top fifth percentile of opioid volume during four 
consecutive calendar quarters.  
 
Domain 1 findings: PDMP impact on opioid prescribing behavior 
 Our literature search identified 11 studies that investigated the efficacy of prescription 
drug monitoring programs on opioid prescribing behavior (Table 3).   The effect of PDMPs on 
opioid prescribing behavior is one of the most studied of the three domains we investigated.   
There was an expansive time period covered by these studies, ranging from as early as 1999 to as 
late as 2015.  In quantifying changes in opioid prescribing behavior, total opioid volumes and the 
number of opioid prescriptions dispensed were commonly used as primary outcome measures.  
Routinely, opioids were converted to their morphine milligram equivalents (MME) to adjust for 
differences in opioid potency.  Overall, findings were mixed on whether the implementation of 
prescription drug monitoring programs were associated with significant reduction in opioid 
prescribing behavior. 
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 Nine out of the 11 studies included were observational studies that extracted data from a 
diverse set of databases to analyze opioid trends in relation to PDMP implementation.  Four 
studies obtained their findings by comparing PDMP states to non-PDMP states in the same time 
interval.  Four studies employed a before-and-after design that evaluated changes in opioid 
dispensing rates as a response to PDMP implementation.  Rutkow et al. and Chang et al. used a 
combination of both study designs.  In both studies, the opioid dispensing rates in Florida were 
compared pre- and post-PDMP implementation.31  Georgia, which had neither an established 
PDMP nor pill mill legislation at the time, was used as a control for additional comparison.    
 Two experimental studies evaluated the effect of PDMP review on opioid prescribing 
practices in an emergency department (ED) setting.25,26  Despite being conducted in different 
geographic locations and in different time periods, both study designs were strikingly similar.  In 
both studies, ED providers were asked about anticipated pain prescriptions pre- and post-review 
of a patient’s PDMP data.  The primary outcome measure was the frequency of change in opioid 
prescriptions after review of patient PDMP data.  Interestingly, despite the similarities in 
methodology, the findings were remarkably different.  Baehren et al. demonstrated that 
utilization of PDMPs resulted in a significant reduction in the opioid prescriptions; 61% of 
patients received fewer or no opioids prescribed compared with pre-PDMP predictions.25  
Conversely, Weiner and colleagues could not show that PDMP review resulted in any significant 
reduction in opioid prescribing behavior.26  In Weiner et al.’s experiment, only 9.5% of ED cases 
showed a modification in opioid prescribing, with 6.5% of patients actually receiving more 
opioids than previously planned.26 
 There were three studies identified that specifically examined the effectiveness of certain 
PDMP characteristics in changing opioid prescribing behavior.24,27,34  Wen et al. described the 
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effectiveness of mandates that required provider registration or use; all mandates were associated 
with a nine to ten percent reduction in Schedule II opioid prescriptions.  Interestingly, there was 
no significant difference in the effect between mandates that required registration versus 
mandates that required utilization.   Paulozzi et al.’s study revealed that states that proactively 
generated PDMP reports for providers, dispensers, and law enforcement did not have any 
significant reduction in total opioid volume rates when compared to other PDMP states.27  
Lastly, Brady et al. evaluated three distinct PDMP characteristics: (1) the governing agency, (2) 
the statutory requirements for committee oversight, and (3) the presence of laws that explicitly 
impose no expectation on providers to use PDMPs.34  In this study, there was a reduction of 
opioids dispensed when PDMPs were governed by state health departments, when there was no 
statutory requirement for committee oversight, or when there was no explicit provision in the law 
that exempted providers from the obligation of accessing the state PDMP database. 
Table 4.  Studies of Prescription Drug Monitoring Program Impact on Patient Behavior 
(Domain 2) 
First 
Author, 
Year  
Outcome Measure Design/Methods Findings 
Evidence 
for PDMP 
Impact 
M
ea
ra
, 2
01
6 
[35
]  
§ Annual prevalence of 
beneficiaries with 
four or more opioid 
prescribers 
§ Annual prevalence of 
prescriptions yielding 
a daily MMEa of 
more than 120 mg 
Comparison: post-PDMPa 
states 
Control:  pre-PDMP states 
Time:  2006-2012 
Statistical method: 
logistic regression 
modeling 
In the post-PDMP period 
within a state, no 
significant reduction was 
seen in patients with four 
or more opioid prescribers 
(-0.14 percentage points). 
 
No significant decline was 
seen with a daily MME of 
more than 120 mg (0.27 
percentage points).   
No 
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Su
rra
tt,
 2
01
4 
[36
]  
§ Diversion rates for 
each opioid class 
Comparison:  post-PDMP 
in Florida 
Control:  pre-PDMP in 
Florida 
Time:  2009-2012 
Statistical method: 
multilevel logistic 
regression modeling 
Significant declines were 
observed in the average 
diversion rates for 
oxycodone (slope -1.31), 
morphine (slope -0.13), 
and methadone (slope -
0.23). 
 
The diversion rate for 
hydrocodone also trended 
downward but did not 
reach statistical 
significance.   
Yes 
Re
ifl
er
, 2
01
2 
[37
] 
§ Number of cases of 
intentional exposure 
to opioids 
Comparison:  PDMP 
states 
Control:  non-PDMP 
states 
Time:  2003-2009 
Statistical method: 
logistic regression 
modeling 
Compared to states with 
PDMPs, states without 
PDMPs had a 0.2% 
increase in intentional 
opioid exposures per 
quarter. 
Yes 
A
li,
 2
01
7 
[38
] 
§ Non-medical opioid 
use in the past year 
§ Number of 
respondents who 
received opioids for 
non-medical use from 
two or more 
prescribers 
Comparison:  36 PDMP 
states 
Control:  14 non-PDMP 
states 
Time:  2004-2014 
Statistical method: 
logistic regression 
modeling 
Having an operational 
PDMP is associated with a 
reduction of approximately 
10 days of non-medical 
opioid use in the past year. 
 
PDMPs are associated with 
a 56% reduction in receipt 
of nonmedical opioids 
from two or more doctors. 
Yes 
Comparison:  PDMP 
states with mandatory 
enrollment or access laws 
Control:  PDMP states 
without mandatory 
enrollment or access laws 
Time:  2004-2014 
Statistical method: 
logistic regression 
modeling 
There is a reduction of 
approximately 20 days of 
non-medical opioid use in 
the past year if the PDMP 
has provisions that require 
mandatory enrollment and 
access by providers. 
 
PDMPs with mandatory 
access provision is 
associated with an 80% 
reduction in the odds of 
having two or more doctors 
as a source of non-medical 
opioids.   
Yes 
a MME morphine milligram equivalent; PDMP prescription drug monitoring programs 
Prescription drug monitoring programs: a response to the opioid epidemic    14 
 
Domain 2 findings: PDMP impact on patient behavior 
There were only four studies identified that evaluated the effect of PDMPs on patient 
behavior (Table 4).  Each study used a different primary outcome measure to quantify changes in 
patient behavior.  These measures included incidence of intentional opioid exposures, opioid 
diversion rates, and the number of beneficiaries with multiple opioid prescribers.  The time 
period covered by these studies ranged from 2003 to 2014.  Two studies compared PDMP states 
to non-PDMP states in the same time period.  Two studies used a before-and-after design, with 
one study that compared pre- and post-PDMP implementation in only a single state, Florida. 
The findings from the three studies were varied.  Meara et al. showed that PDMP 
implementation was not correlated with any significant decrease in the amount of Medicare 
beneficiaries with four or more opioid providers.35  Ali et al. also demonstrated similar findings 
with more compelling reductions in doctor shopping associated with PDMPs with mandatory 
access laws.38  However, Reifler et al. found a 0.2% quarterly increase in intentional opioid 
exposure cases in states without PDMPs compared to states with a PDMP.37  In comparing 
opioid diversion rates in Florida, Surrat et al. observed a decrease in the average diversion rates 
for oxycodone, morphine, and methadone.36  There was also an observable decrease in 
hydrocodone diversion rates, but not enough to reach statistical significance.   
Table 5.  Studies of Prescription Drug Monitoring Program Impact on Population Health 
Outcomes (Domain 3) 
First 
Author, 
Year  
Outcome Measure Design/Methods Findings 
Evidence 
for PDMP 
Impact 
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Li
, 2
01
4 
[28
]  
§ Drug overdose 
mortality 
Comparison:  31 PDMPa 
states 
Control:  20 non-PDMP 
states 
Time:  1999-2008 
Statistical method: 
multilevel negative 
binomial logistic 
regression modeling 
PDMPs were associated 
with an 11% increase in 
drug overdose mortality, 
with the greatest increase 
seen in PDMPs that 
imposed no expectation on 
practitioners.b 
 
Impact of PDMPs on drug 
overdose mortality varied 
across states, ranging from 
35% decrease (Michigan) 
to a more than three-fold 
increase (Nevada).   
No 
M
ea
ra
, 2
01
6 
[35
]  
§ Number of non-fatal 
prescription opioid 
overdoses 
Comparison: pre-PDMP 
states 
Control:  post-PDMP 
states 
Time:  2006-2012 
Statistical method: 
logistic regression 
modeling 
The association between 
PDMPs and rates of non-
fatal prescription-opioid 
overdose was not 
significant.    
No 
Pa
tri
ck
, 2
01
6 
[39
]  
§ Annual rate of 
opioid-related 
overdose deaths 
Comparison: PDMP states 
Control:  non-PDMP 
states 
Time:  1999-2003 
Statistical method: 
interrupted time-series 
linear regression model 
States that implemented a 
PDMP had a lower opioid-
related overdose death rate 
(6.19 per 100,000), 
compared to non-PDMP 
states (6.50 per 100,000).   
There was an associated 
1.12 decline in opioid-
related overdose deaths per 
100,000 after PDMP 
implementation. 
Yes 
Comparison: PDMP states 
that monitored at least four 
drug schedules 
Control:  PDMP states 
that monitored less than 
four drug schedules 
Time:  1999-2003 
Statistical method: 
interrupted time-series 
linear regression model 
PDMPs that monitored 
four or more drug 
schedules were associated 
with a 0.55 reduction in 
opioid-related overdose 
deaths per 100,000.c   
Yes 
Comparison: PDMP states 
that updated data at least 
weekly 
Control:  PDMP states 
that did not update data at 
least weekly 
Time:  1999-2003 
Statistical method: 
interrupted time-series 
linear regression model 
PDMPs that updated data 
at least weekly were 
associated with a 0.82 
reduction in opioid-related 
overdose deaths per 
100,000.c   
Yes 
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Comparison: PDMP states 
with registration or use 
mandates 
Control:  PDMP states 
without registration or use 
mandates 
Time:  1999-2003 
Statistical method: 
interrupted time-series 
linear regression model 
State requirements for 
registration with or use of 
PDMP did not show 
significant effect on 
opioid-related overdose 
deaths.c 
No 
Pa
rd
o,
 2
01
7 
[40
] 
§ Opioid death rates  Comparison: PDMP states 
that were categorized 
based on strength using a 
points-based systemd 
Control:  non-PDMP 
states 
Time:  1999-2014 
Statistical method: two-
way fixed-effects model 
There was a one percent 
reduction in opioid death 
rates for each point 
assigned to a state’s PDMP 
strength score.  
 
PDMP states with strength 
scores in the third quartilee 
were associated with an 
18% reduction in opioid 
death rates compared to 
states with no PDMP. 
Yes 
Pa
ul
oz
zi
, 2
01
1 
[27
] 
§ Rate of drug 
overdose mortality 
§ Rate of opioid 
overdose mortality 
Comparison: 19 PDMP 
states 
Control:  31 non-PDMP 
states 
Time:  1999-2005 
Statistical method: linear 
regression models for 
multiple parallel time 
series (panel regression) 
The differences between 
PDMP and non-PDMP 
states were not statistically 
significant for either mean 
drug overdose and opioid-
related overdose mortality 
rates. 
No 
Re
ism
an
, 2
00
9 
[41
] 
§ Inpatient prescription 
opioid treatment 
admissions 
Comparison: 14 PDMP 
states 
Control:  36 non-PDMP 
states 
Time:  1997-2003 
Statistical method: time-
series linear regression 
model 
PDMP states have lower 
increases in opioid 
admissions during study 
period and the gap widened 
with each successive year. 
 
A patient admitted to an 
inpatient drug abuse 
rehabilitation in a PDMP 
state was less likely to be 
admitted for prescription 
opioid drug abuse (OR 
0.775)a. 
Yes 
Re
ifl
er
, 2
01
2 
[37
]  § Number of opioid treatment admissions 
Comparison:  PDMP 
states 
Control:  non-PDMP 
states 
Time:  2003-2009 
Statistical method: 
logistic regression 
modeling 
Opioid treatment 
admissions increase 4.9% 
in non-PDMP states and 
2.6% in PDMP states 
Yes 
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D
el
ch
er
, 2
01
5 
[42
]  
§ Oxycodone-caused 
deaths 
Comparison:  post-PDMP 
in Florida 
Control:  pre-PDMP in 
Florida 
Time:  2003-2012 
Statistical method: 
logistic regression 
modeling 
In Florida, there was a 25% 
decline in oxycodone-
caused deaths after PDMP 
implementation.  For a 
system-wide increase of 
one PDMP query per 
provider, oxycodone-
caused deaths declined at a 
rate of 0.229 persons per 
month.   
Yes 
M
au
gh
an
, 2
01
5 
[43
] 
§ Rates of opioid-
related EDa visits 
Comparison:  11 post-
PDMP metropolitan areas 
in the United States 
Control:  11 pre-PDMP 
metropolitan areas in the 
United States 
Time:  2004-2011 
Statistical method: 
logistic regression 
modeling 
Rates of opioid-related ED 
visits increased in all 
metropolitan areas, and the 
increase was similar when 
grouped by year of PDMP 
implementation.   
No 
Br
ow
n,
 2
01
7 
[32
] § Prescription opioid dose overdoses 
Comparison: post-PDMP 
implementation 
Control:  pre-PDMP 
implementation 
Time:  2010-2015 
Statistical method: 
interrupted time-series 
analysis 
There was no significant 
difference in the 
prescription opioid 
overdose slopes after 
PDMP implementation 
compared to before PDMP 
implementation. 
No 
N
am
, 2
01
7 
[44
] 
§ Prescription drug 
overdose mortality 
rates 
Comparison: PDMP states 
Control:  non-PDMP 
states 
Time:  1999-2014 
Statistical method: 
logistic regression 
modeling 
PDMPs were not 
associated with reductions 
in prescription opioid 
overdose mortality rates 
relative to expected rates in 
non-PDMP states. 
 
PDMPs were associated 
with increased mortality 
rates, but associations were 
not statistically significant.   
No 
Ph
ill
ip
s, 
20
17
 [4
5 ] 
§ Mean age-adjusted 
opioid-related 
mortality 
Comparison: PDMP states 
Control:  non-PDMP 
states 
Time:  2011-2014 
Statistical method: 
interrupted time-series 
analysis 
PDMPs were associated 
with an increase of 
11.4% in mean age-
adjusted opioid-related 
mortality. 
 
For every additional 
year since enactment, 
mortality rate increased 
by 5.8% for states with a 
PDMP compared to 
states without a PDMP. 
No 
a  PDMP prescription drug monitoring programs; PDAP prescription drug abuse policy system; OR odds ratio; ED 
emergency department 
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b  Of the 31 implemented PDMPs included in the study, 11 contained provisions exempting providers from the 
obligation to access the state PDMP database.  
c  West Virginia was excluded in this analysis because it was an extreme outlier, with an opioid-related overdose 
death rate nearly twice as high as that of the next highest state.  It also implemented a program early in the study 
period.   
d  Specific features of PDMPs were assigned a score from zero to four based on the strength of evidence provided by 
analytic studies.  For example, requirements for providers to check PDMPs prior to prescribing were assigned four 
points, while features that required law enforcement access were only allotted one point. 
e  PDMP strength scores were collapsed into four different quartiles (scores 1-7=1, scores 8-10=2, scores 11-13=3; 
and scores 14-21=4). 
 
Domain 3 findings: PDMP impact on opioid-related population health outcomes 
Database results yielded 12 studies that assessed the effect of PDMPs on opioid-related 
population health outcomes (Table 5).  Primary outcome measures in these studies were 
commonly related to opioid-related mortality rates.   Opioid mortality rates were derived from a 
variety of different databases, including but not limited to the National Center for Health 
Statistics and Medicare claims data(Table 2).  The years covered by these studies ranged from 
1999 to 2015.  Eight studies compared PDMP states to non-PDMP states in the same time 
period.  Only four studies used a before-and-after design that compared opioid population health 
outcomes pre- and post-PDMP implementation.  Similar to the other domains, the results of 
PDMP effects on opioid-related health outcomes were mixed.  
Of the seven studies that looked at opioid-related drug mortality rates, four studies did 
not support an association of PDMPs with a reduction in opioid overdose mortality rates (Table 
5).27,28  Using data from the National Center for Health Statistics, Li et al. revealed that there was 
an 11% increase in drug overdose mortality in PDMP states compared to non-PDMP states.  
However, in Li’s study, the impact of PDMPs on opioid-related overdose mortality had wide 
variability across states (Table 5).28  
There were three studies that used opioid-related admissions and/or ED visits as the 
primary outcome measure (Table 5).  In two studies that directly compared PDMP states to non-
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PDMP states, PDMP states were associated with lower rates of opioid-related treatment 
admissions.37,41  However, Maughan and colleague’s study on 11 metropolitan areas pre- and 
post-PDMP implementation showed no significant reduction in opioid-related ED visits when 
PDMPs were enacted.43  
In their respective papers, Patrick and Pardo delved further in evaluating the effectiveness 
of specific PDMP characteristics.39,40  Patrick et al. showed that certain PDMP characteristics, 
such as the monitoring of at least four drug schedules and requiring weekly system updates, were 
associated with reduction in opioid-related deaths.39  Conversely, there was no statistically 
significant effect of PDMP registration and use mandates on opioid-related deaths.39  
In a unique approach, Pardo et al. designed a strength-based point system to assess the 
cumulative effect of specific PDMP characteristics on opioid-death rates.40  Certain PDMP 
features were assigned a score from zero to four based on strength of evidence from prior 
research.  The highest score of four was assigned to characteristics that were considered to have 
strong evidence-based backing.  After considering all the features of each drug monitoring 
programs, each PDMP was given a summative strength score and categorized into different 
quartiles (Table 5).  Pardo’s research demonstrated that PDMP states with strength scores in the 
third quartile (scores of 11-13) were associated with an 18% reduction in opioid death rates 
compared to states with no PDMP.40  
Discussion 
The current literature evaluating the theoretical benefits of prescription drug monitoring 
programs are well-described but are poorly studied.  Evaluation of prescription drug monitoring 
programs is predicated on the premise that increased monitoring and reporting of opioid 
prescriptions will be associated with corresponding changes in opioid-related outcomes.  High-
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risk drug-seeking behavior, such as obtaining prescriptions from multiple providers or multiple 
pharmacies, can be identified with the utilization of PDMPs.  When these behavior patterns are 
recognized, providers are subsequently expected to reduce their opioid prescribing, thus 
decreasing misuse and diversion and ultimately decreasing opioid-related mortality and 
morbidity.  Therefore, opioid-related outcomes can be categorized into domains that include 
changes in provider opioid-prescribing behavior, overall opioid supply, drug diversion activities, 
and opioid-related morbidity and mortality outcomes.   
Review of current literature reveals mixed effects of prescription drug monitoring 
programs on opioid-related outcomes.  The wide discrepancy in results is likely due to study-
related factors, such as differences in outcome measurements, study design (across-state versus 
within-state comparisons), data sources, exposures, and statistical approaches.  It is these same 
factors that make it difficult to make direct comparisons between study results.   
Additionally, PDMP characteristics vary considerably across states in both legislated 
components and implementation strategies.  Legislated components include the state-mandated 
frequency in which data is entered into the system, the ease of accessing information, the types 
of providers allowed and/or required to register, and the amount of training providers receive in 
the utilization of their state’s system.  Another factor that complicates review is that drug 
monitoring programs were enacted across states at different times, resulting in variable levels of 
provider experience and comfort with their state’s program.   
Limitations 
Conducting a well-designed randomized controlled trial to assess the effectiveness of 
PDMPs is challenging.  Thus, observational cohort studies are increasingly utilized.  The 
strength of observational studies is limited because of susceptibility to bias due to the 
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confounding factors.  As such, sophisticated multivariable techniques are often required to 
account for these factors.  The employment of different analytical approaches across different 
papers makes it difficult to directly compare results from multiple studies.   
Given the variability of the state-specific features of each drug monitoring program, it is 
difficult to assess whether results can be attributed to the establishment of PDMPs and not to 
other possible causes.  For example, Florida’s prescription drug monitoring program and pill mill 
laws were enacted at the same time.  The individual effect of PDMPs in Florida cannot be 
accurately determined because it cannot be separated from the effect of concurrent pill mill 
legislation.  In another example, states with stricter use mandates might have a more rapid 
growth in the opioid epidemic compared to other states.  Without sufficient analytic control such 
confounding factors could lead to biased results, and researchers may fail to find an effect of 
mandates, even if one exists.24   
Furthermore, in comparisons of PDMP states to non-PDMP states, state-to-state 
variability in impact (i.e., heterogeneity of effects) can mask important findings.23  In Li et al.’s 
study, there was an observed 11% increase in opioid-related overdose mortality in PDMP states.  
However, further analysis showed that the impact of PDMPs on opioid mortality varied widely 
across states, ranging from a 35% decrease in Michigan to a greater than three-fold increase in 
Nevada.  Significant state-to-state variability could also be seen in Brady et al.’s study.34  In 
studying the impact of PDMPs on total opioids dispensed, Brady and colleagues showed a 
significant reduction in MMEs dispensed in nine states and a significant increase in eight states. 
Directions for future research 
Although PDMPs across states are similar in basic elements, many characteristics of 
these programs vary from state to state.  Given the heterogeneity of state-specific characteristics 
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of any single drug monitoring program, it is difficult to generalize that the findings in one state 
will hold for other states and at other periods of time.  On the other hand, the inconsistency 
between PDMP characteristics among states can provide valuable insight on specific features 
that are more effective at impacting opioid-related behaviors.   
There were several authors in this review that attempted to address the effectiveness of 
specific PDMP characteristics.  However, in reality, most programs implement multiple features 
and it is difficult to discern the individual effectiveness of a specific feature.  Pardo’s approach 
of utilizing a strength-based scoring system for PDMPs was unique.  Points were designated to 
specific features based on the strength of evidence-based research.  However, if data was not 
available, PDMP characteristics were allotted points based on the opinions of a committee of 
doctors and experts.  While Pardo’s approach attempts to account for the cumulative effects of 
multiple PDMP characteristics, his system is at higher risk for bias once points are no longer 
allotted based on evidenced-based research.  For this reason, how different PDMP features 
impact opioid-related outcomes require closer scrutiny.   
There has been much effort in assessing the potential benefits of prescription drug 
monitoring programs.  However, there is minimal focus on its potential harms.  The most 
frequently touted argument against drug monitoring programs is referred to as the “chilling 
effect”.  The “chilling effect” refers to the hesitance or resistance of providers to prescribe opioid 
analgesics even to appropriate candidates, leaving patients seeking illegitimate means to manage 
their pain.24,46  All of the studies reviewed in this paper did not include data to determine the 
appropriateness of opioid prescribing or non-prescribing.  There is a paucity of research directed 
toward whether prescription drug monitoring programs have a negative impact on a patient’s 
pain management needs. 
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Conclusion 
Literature surrounding drug monitoring programs remains relatively nascent.  As PDMP 
implementation and widespread program reform continues to expand and evolve over time, there 
needs to be continued research on the impact of specific program characteristics to determine 
what is most effective at reducing opioid-related outcomes.  Development of a more 
sophisticated and universal analysis of these programs will provide an evidenced-based 
foundation to help establish drug monitoring programs that reaches their full potential in 
reducing opioid-related harms across the country.    
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